Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Part of paid clinical trials in Austin, Texas.

Sponsor
Westlake Eye Specialists
Study ID
NCT06449352
Phase
PHASE4
Status
Completed

Conditions

  • Normal Tension Glaucoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Netarsudil — DRUG
    netarsudil 0.02%
  • Brimonidine — DRUG
    brimonidine 0.1%

Study Details

A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .

Key Dates

Start date
Jun 13, 2024
Status verified
Oct 2025
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025

Study Design

Enrollment
100 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Netarsudil
    netarsudil 0.02%
  • Active Comparator: Brimonidine
    brimonidine 0.1%

Primary Outcome Measure

Mean diurnal intraocular pressure [ Time Frame: After 6 weeks of treatment ]

Locations (4)

FacilityCityStateZIPSite coordinators
Westlake Eye Specialists - Austin OfficeAustinTexas78746-
Westlake Eye Specialists - Killeen OfficeKilleenTexas76549-
Westlake Eye Specialists - Kyle OfficeKyleTexas78640-
Westlake Eye Specialists - New Braunfels OfficeNew BraunfelsTexas78130-

Find similar trials in Austin, TX

By research site
Westlake Eye Specialists - Austin Office· Austin, TXWestlake Eye Specialists - Killeen Office· Killeen, TXWestlake Eye Specialists - Kyle Office· Kyle, TXWestlake Eye Specialists - New Braunfels Office· New Braunfels, TX

Related Studies